Skip to main content
UAE Ends Medicine Monopolies: New Pharma Rule to Lower Drug Costs

UAE Announces New Pharmaceutical Rule to Break Medicine Monopolies and Lower Drug Costs

In a landmark move for the Middle Eastern healthcare sector, the Emirates Drug Establishment (EDE) has officially activated a new regulatory mechanism aimed at ending the "single-agent" monopoly over medical products in the UAE.

As of February 24, 2026, pharmaceutical manufacturers are now required to register multiple authorized agents for each medicine, moving away from exclusive distribution rights that have historically kept prices high.

Key Objectives of the New Rule

  • Breaking Monopolies: Prevents any single distributor from having exclusive control over the pricing and availability of vital medications.
  • Lowering Drug Costs: Increased competition among various authorized agents is expected to drive market prices down for consumers.
  • National Drug Security: By diversifying distribution channels, the UAE ensures that the supply chain is resilient against global disruptions.
  • Improved Market Access: Facilitates a faster and more efficient distribution of medicines across all Emirates.

Impact on the Industry

This regulation, rooted in Federal Decree-Law No. (38) of 2024, positions the UAE as a leader in patient-centric pharmaceutical policy. For global drug makers, this means a shift in how they manage their intellectual property and distribution agreements within the region. It opens doors for more logistics players and provides a transparent framework for market entry.

For healthcare providers and patients, the primary benefit remains affordability and consistent access to life-saving treatments without the bottleneck of a single supplier.

Stay tuned to e-Pharma Times for more updates on global pharmaceutical regulations and intellectual property trends.

Comments

Post a Comment

Popular posts from this blog

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more

Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

The pharma monster has offered five of its ophthalmic medications to eye treatment organization Harrow for a one-time frame installment of $130 million, or more extra achievement installments of $45 million. The deal incorporates waterfall medical procedure recuperation eye drops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, irritation eye drops Maxidex and the injectable Triesence. The arrangement makes Harrow famous into "an administrative role in the U.S. ophthalmic drugs market," Imprint L. Baum, Harrow's Chief and executive, said in an assertion. "We know these items quite well and have long appreciated and respected them for the worth they have conveyed to great many U.S. eyecare experts and a huge number of their patients," Baum added. The arrangement will probably close during the main quarter of 2023. A while later, Novartis will in any case possess the items beyond the U.S. U.S. Novartis "stays focused on patients by supporting ad...
Post a Comment
Read more
Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Post a Comment
Read more